About Us: Leadership
Breaking Boundaries Takes Bold Leadership
Our experienced leadership team brings a proven track record in the discovery, development and commercialization of groundbreaking therapies that transform patient care in a variety of disease areas. Together, our leaders advance our culture of scientific rigor and an operational mindset, maintaining an unwavering focus on the discovery and development of therapies for the patients who stand to benefit most.
Josh Lehrer, M.D., M.Phil., FACC
Chief Executive Officer
Dr. Josh Lehrer is the chief executive officer at Graphite Bio. In this role, Dr. Lehrer bridges his clinical background as a practicing physician with decades of experience at global biopharmaceutical companies leading businesses and high-functioning teams across all stages of drug development.
Previously, Dr. Lehrer served as chief medical officer at Global Blood Therapeutics (GBT) where he led the innovative clinical development strategy for sickle cell disease treatment Voxelotor from pre-IND stages through commercial launch, including playing an integral role in raising over $1 billion to fund the product’s development and launch. At GBT, Dr. Lehrer also built a 45-member development organization and oversaw all clinical development and operations for the company during a period of rapid growth and pipeline advancement. Dr. Lehrer has also served in leadership roles at Genentech in clinical development and business development, as well as attending physician roles at Stanford University Medical Center and the Palo Alto Veteran’s Affairs Health System.
Dr. Lehrer earned his Doctor of Medicine at the University of California, San Francisco (UCSF), School of Medicine and completed his residency at UCSF in internal medicine. He holds an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. Dr. Lehrer served as a clinical and postdoctoral fellow in cardiovascular medicine at Stanford University and attended the Institute for Entrepreneurship at the Stanford Graduate School of Business.
Chief Technical Officer
Jerry Cacia is the chief technical officer at Graphite Bio. In this role, Mr. Cacia is responsible for leading the development of the overall manufacturing strategy and technical operations in support of Graphite Bio’s gene editing programs as they advance to the clinic. Mr. Cacia is advancing the development and implementation of a robust manufacturing strategy to ensure the advancement of Graphite Bio’s clinical programs and assure a clear and scalable path to patients.
Mr. Cacia has proven experience in the development of manufacturing processes and quality control systems across multiple therapeutic modalities. During his 32-year career at Genentech and Roche, he held various senior leadership positions in technical development, manufacturing and quality. In his most recent position, Jerry served as head of global technical development at Roche during which time he supported a pipeline that included over 80 new molecular entities and more than 100 development projects in various stages, including a number of cell, gene and individualized neoantigen therapy programs.
Mr. Cacia holds a Bachelor of Science degree in Biological Sciences from the University of California at Santa Cruz.
Christine Garrett, Ph.D., PMP
Chief of Staff and Senior Vice President of Operations
Christine (Chris) Garrett is chief of staff and senior vice president of operations at Graphite Bio. In this role, Dr. Garrett is responsible for providing strategic guidance to successfully execute key business initiatives to optimize and support the growth of the company.
Dr. Garrett brings more than 20 years of industry experience leading high-performing, cross-functional teams at global biopharmaceutical companies to advance the development and life-cycle management of pipeline and approved therapies. She most recently worked at Bristol Myers Squibb (BMS) overseeing late development project management for the global R&D organization and significantly contributed to the integration of development programs from Celgene and Myokardia into the BMS portfolio. Dr. Garrett has also held senior leadership roles in global R&D project and portfolio management at Leo Pharma and Celgene. Earlier in her career, she worked at Novartis in various program management roles of increasing responsibility. Prior to joining the biopharmaceutical industry, she led and executed projects to develop antimicrobial preservatives for a specialty chemicals company.
Dr. Garrett received her Bachelor of Science in Chemistry from the Rochester Institute of Technology and her Ph.D. in Organic Chemistry from MIT. She also holds certificates in project management and pharmaceutical business development.
Jane Grogan, Ph.D.
Chief Scientific Officer
Dr. Jane Grogan is the chief scientific officer at Graphite Bio. In this role, she oversees Graphite Bio’s clinical research and development efforts, leveraging the company’s targeted gene integration platform technology in new therapeutic areas to impact patients and support the continued growth of the company’s world-class research group.
Prior to joining Graphite Bio, Dr. Grogan served as chief scientific officer and a member of the executive leadership team at ArsenalBio, a programmable cell therapy company, where she established the research organization and preclinical pipeline of cell therapies for solid tumors. From 2004-2019, Dr. Grogan distinguished herself as an influential scientist throughout her tenure at Genentech, a member of the Roche Group. As head of adaptive tumor immunity and principal scientist of cancer immunology discovery research at Genentech, Dr. Grogan oversaw discovery research programs from target identification through clinical development, and she managed in-licensing business partnerships and external development collaborations. She is widely-recognized as the founder and original host of the popular podcast series “Two Scientists Walk into a Bar.”
During her career, Dr. Grogan has published over 60 papers in a wide array of journals and is the inventor on over 20 patents. She obtained her Ph.D. from Leiden University, The Netherlands, and her BSci (Hons) degree from the University of Melbourne, Australia. Dr. Grogan completed her post-doctoral training as an Alexander von Humboldt Fellow at the German Rheumatism Research Centre Berlin (DRFZ) and as a Howard Hughes Fellow at the University of California San Francisco (UCSF).
Philip P. Gutry
Chief Business Officer
Mr. Gutry serves as chief business officer at Graphite Bio. Mr. Gutry brings to this role extensive business development, strategy, finance and investor relations experience with a successful track record of raising capital and establishing partnerships for biotech companies.
Mr. Gutry most recently worked at Kronos Bio, a clinical-stage oncology company focused on targeting dysregulated transcription, where he served as chief business officer. In this role, he led the acquisition of Gilead’s spleen tyrosine kinase inhibitor portfolio, which transformed Kronos into a clinical-stage company and was the primary catalyst for raising $500M in equity capital, including the company’s Initial Public Offering. Previously, Mr. Gutry served in senior business development and finance roles at Regeneron Pharmaceuticals, MPM Capital and Gilead Sciences during which he led or managed over 30 transactions raising over $2 billion in equity, debt and R&D funding.
Mr. Gutry received his A.B. in Earth Sciences from Dartmouth College and his M.B.A. in Healthcare Management from The Wharton School.
Chief People Officer
Julia Tran is the chief people officer at Graphite Bio. Ms. Tran brings to Graphite Bio more than 20 years of experience building and growing passionate, mission-driven organizations that are committed to developing innovative solutions to tackle some of the biggest global challenges in biotech, cleantech and cybersecurity.
As a people executive for biotech companies like Amyris, Ms. Tran played a pivotal role in scaling it from early-stage development through commercialization to IPO. Amyris, in partnership with the Bill and Melinda Gates Foundation, developed artemisinic acid-producing yeast strains through their novel synthetic biology platform and made it available to Sanofi on a royalty-free basis via OneWorld Health, which distributed it to malaria patients in the developing world. The company went on to deliver impactful cleantech products such as second-generation biofuels, chemicals and consumer healthcare products. Additionally, Ms. Tran worked on the commercial organizational buildout for Millennium Pharmaceuticals’ launch of Velcade for the treatment of multiple myeloma and Integrilin for acute coronary syndrome. Notably, at CV Therapeutics, she led the recruitment efforts for the first national sales force for their flagship product, Ranexa, for chronic angina. Ms. Tran brings an incredibly diverse background to Graphite Bio. In addition to her biotech background, she brings tech executive leadership experience. Most recently, as a Silicon Valley entrepreneur, she co-founded a venture-backed cybersecurity company, Blue Lava Inc., where she served as both chief operating officer and chief community officer from concept to commercialization.
Ms. Tran holds a Bachelor of Arts degree in Political Science from Boston College.
Chief Financial Officer
Ms. Young is the chief financial officer at Graphite Bio. In this role, Ms. Young oversees the company’s finance, investor relations and corporate communications functions, and plays a key role in overall corporate strategy.
Previously Ms. Young served as senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering large cap and small-mid-cap biotechnology companies. Prior to joining Cantor Fitzgerald in 2018, Ms. Young held senior biotech analyst positions at Credit Suisse and Deutsche Bank. Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions.
Ms. Young earned a B.A. in Economics and Spanish from Duke University. She currently serves on the board of directors for BUILD NYC.